| 作 者 |
McVary, K. T., Gittelman, M. C., Goldberg, K. A., Patel, K., Shore, N. D., Levin, R. M., Pliskin, M., Beahrs, J. R., Prall, D., Kaminetsky, J., Cowan, B. E., Cantrill, C. H., Mynderse, L. A., Ulchaker, J. C., Tadros, N. N., Gange, S. N., Roehrborn, C. G. |
| abstract |
Rezum is powered by convective water vapor energy, and it inserts water vapor jet into the prostate gland with thermal energy. The energy is restricted in defined area till the prostate capsule. It is considered as a minimally invasive therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia and the previous study showed short-term good outcomes with preserved sexual function. To evaluate the long-term effect and possible adverse events, this study presents the final 5-year outcomes of the multicenter randomized sham-controlled trial of Rezūm™ for treatment of benign prostatic hyperplasia. And among the 197 males aged >50 years old with IPSS ≥13, those treated with Rezūm have significant improvement of lower urinary tract symptoms (IPSS reduced 48%, QOL increased 45%, maximum flow rate improved 44%) and remaining durable through 5 years with no reports of surgical related sexual dysfunction. Rezūm is considered a minimally invasive treatment with significant and durable symptom relief and providing successful treatment to obstructive lateral and middle lobes.
|
